Market Scope Market Dynamics Drivers Rising Prevalence of Type 2 Diabetes and Obesity A major factor driving the adoption of GLP-1 analogues is the rise in diabetes and obesity cases worldwide
doi: 10.3389/fphar.2026.1795174 Received 24 January 2026 Revised 09 April 2026 Accepted 13 April 2026 Published 30 April 2026 Volume 17 - 2026 Edited by Nabil Eid, IMU University, Malaysia Reviewed by MoezAlIslam Ezzat Faris, Applied Science Private University, Jordan Payal Bhatnagar, International Medical University, Malaysia Gehan El Akabawy, Ajman University, United Arab Emirates Updates Copyright 2026 Ma, Hao, Wang, Qiu, Cao, Deng, Wang, Li, Zhang, Wei, Yao, Gao, Yi, Liu and Li
If increased intraocular pressure is not corrected, it can lead to vision loss over time, often beginning with peripheral vision
73 Of major concern are potentially severe complications (septicaemia, infective endocarditis and transmission of blood-borne infections) of IV administration of GSH by people with no health qualifications
The Path Forward: Balancing Innovation, Safety, and Access The ongoing legal battles surrounding GLP-1 agonists serve as a microcosm of the broader challenges in the pharmaceutical landscape
Effects of Insulin-like Growth Factors (IGF) on Pancreatic Islet Function in IGF Binding Protein-1 Transgenic Mice